Objective To evaluate the clinical outcome after aPL (antiphospholipid antibodies)
disappearance in primary APS patients. Methods From a cohort of 70 patients with primary …

Background Antiphospholipid syndrome (APS) is an acquired hypercoagulable condition
associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following …

Recommended treatment for patients with primary antiphospholipid syndrome (APS) after a
thrombotic event is long-term anticoagulation. Few patients with APS and previously positive …

Antiphospholipid antibody syndrome is a well-recognized cause of hypercoagulability and
has multiple manifestations. Patients with an unexplained thrombotic event should be …

OBJECTIVES: To assess risk factors for a first thrombotic event in confirmed
antiphospholipid (aPL) antibody carriers and to evaluate the efficacy of prophylactic …

The presence of antiphospholipid antibodies has been shown to be related to an increased
risk of thrombotic events. In patients with definite antiphospholipid syndrome (APS), that is …

Although much progress has been made in the past 20 years on understanding the clinical
features of antiphospholipid syndrome (APS), investigation into its epidemiology has been …

Objective This article aims to analyse the rate of antiphospholipid antibodies (aPL)
negativisation in patients with antiphospholipid syndrome (APS), and to evaluate potential …

Introduction: Antiphospholipid syndrome (APS) is an acquired autoimmune thrombophilia
associated with the presence of persistent antiphospholipid antibodies (aPL). Owing to …

OBJECTIVE: We carried out a prospective analysis of clinical and analytical findings in
individuals with antiphospholipid antibodies (aPL). METHODS: We prospectively studied …